Evaluating the role of quality assessment of primary studies in systematic reviews of cancer practice guidelines by Brouwers, Melissa C et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Medical Research 
Methodology
Open Access Research article
Evaluating the role of quality assessment of primary studies in 
systematic reviews of cancer practice guidelines
Melissa C Brouwers*1,2, Mary E Johnston1,2, Manya L Charette1,2, 
Steve E Hanna1, Alejandro R Jadad3 and George P Browman1,2,4
Address: 1Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada, 2Program in Evidence-based Care, 
Cancer Care Ontario, Hamilton, Canada, 3University of Toronto and University Health Network, Toronto, Canada and 4Hamilton Regional 
Cancer Centre, Hamilton, Canada
Email: Melissa C Brouwers* - mbrouwer@mcmaster.ca; Mary E Johnston - johnston@mcmaster.ca; Manya L Charette - charet@mcmaster.ca; 
Steve E Hanna - hannas@mcmaster.ca; Alejandro R Jadad - ajadad@uhnres.utoronto.ca; George P Browman - georgebr@cancerboard.ab.ca
* Corresponding author    
Abstract
Background: The purpose of this study was to evaluate the role of study quality assessment of
primary studies in cancer practice guidelines.
Methods: Reliable and valid study quality assessment scales were sought and applied to published
reports of trials included in systematic reviews of cancer guidelines. Sensitivity analyses were
performed to evaluate the relationship between quality scores and pooled odds ratios (OR) for
mortality and need for blood transfusion.
Results: Results found that that whether trials were classified as high or low quality depended on
the scale used to assess them. Although the results of the sensitivity analyses found some variation
in the ORs observed, the confidence intervals (CIs) of the pooled effects from each of the analyses
of high quality trials overlapped with the CI of the pooled odds of all trials. Quality score was not
predictive of pooled ORs studied here.
Conclusions: Had sensitivity analyses based on study quality been conducted prospectively, it is
highly unlikely that different conclusions would have been found or that different clinical
recommendations would have emerged in the guidelines.
Background
Quality assessment of trials included in systematic reviews
of evidence is a resource intensive and scientifically con-
troversial endeavour. On the one hand, the routine use of
quality assessment in the development of systematic
reviews is encouraged by the Evidence-based Practice
Center Program of the Agency for Healthcare Research &
Quality (AHRQ) and the Cochrane Collaboration, two
well respected groups that coordinate a substantial
number of systematic reviews [1-3]. Indeed, West et al
released a 2002 evidence report sponsored by the AHRQ
comparing and contrasting various systems to rate the
strength and quality of research evidence to assist in these
activities [4]. Furthermore, many journal editors consider
it important to include an assessment of study quality in
reports featuring meta-analyses [3].
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The concept of incorporating study quality assessment
into systematic review methodology has also found
empirical support. There is evidence that studies of lower
methodological quality tend to report larger treatment
effects than high quality studies [5-7]. For example,
Moher and his colleagues found a 34% greater estimate of
treatment effect for low quality versus high quality trials
and a 37% greater estimate of treatment effect for inade-
quately concealed versus adequately concealed trials asso-
ciated with reviews addressing a variety of clinical
conditions [5]. Similar bias was found by Schultz and his
colleagues [6] in their analysis of trials included in the
Cochrane Collaboration's Childbirth and Pregnancy
reviews. In addition, Colditz and colleagues found that
nonrandomized and open studies were more likely to
produce positive treatment effects than randomized and
double-blinded studies [7].
Although this seminal work yields compelling results,
these findings are not universal and the issue is not with-
out detractors [8-14]. Some studies have found no reliable
relationship between quality score and effect size [10-12]
and another has found that low study quality was associ-
ated with diminished effect sizes [13]. Further, Juni et al
[14] found the relationship between study quality and
effect size depended on the scale used in the assessment.
Together these results suggest the study quality issue is
controversial and that the merits of this methodological
step in systematic review requires thoughtful analysis.
Indeed, West et al conclude with recommendations advo-
cating for research dedicated to comparing quality rating
systems and the role of quality assessment within individ-
ual clinical contexts and for studies targeted at determin-
ing specific quality factors that make a difference in final
quality scores [4].
The Practice Guidelines Initiative of the Cancer Care
Ontario's Program in Evidence-based Care (PEBC) uses
the Guidelines Development Cycle to create cancer prac-
tice guidelines comprised of a systematic review of the
research literature, an interpretation and consensus of the
evidence by members of the guideline development team,
clinical recommendations informed by the evidence, and
an external review process by Ontario clinicians [15-19].
We face the challenge of balancing scientific rigour and
the timely production of guideline documents in an envi-
ronment defined by limited financial and human
resources. Hence, we try to approach our methodological
decisions with a critical scientific and practical eye. We
took note of the growing controversy in the study quality
assessment literature and conducted an evaluation,
reported below, to evaluate the benefits of assessing the
quality of each study included in our systematic reviews.
Our overall objective was to decide whether to augment
our current practice of simply describing study character-
istics to also incorporate study quality assessment as a
routine formal component of the guideline development
methodology. The evaluation was conducted in three
steps, each of which was designed to address three specific
issues:
1. What valid and reliable quality assessment instrument
would be most appropriate for our context?
2. How is study quality currently being used in published
systematic reviews of cancer trials and what is the relation-
ship between effect size and study quality in this disease
area?
3. What impact would study quality assessment have on
the clinical recommendations made in evidence-based
practice guidelines developed by the PEBC?
Methods
Search for a valid and reliable quality assessment tool for 
the PEBC context
For a comprehensive review of the strengths and weak-
nesses of quality assessment instruments, readers are
referred to the 2002 West et al. evidence report commis-
sioned by the AHRQ [4]. For our study, which began
before the release of this report, we used components of
Moher et al's definition of study quality that are related to
internal validity (i.e., design, conduct and analysis) [20]
and updated his 1992 published reports of check lists and
scales used to measure the phenomenon [21]. We
searched the Medline database using the following search
strategy: (quality adj rat:).tw OR (quality adj assess:).tw.
OR (quality adj scale:).tw. OR (quality adj checklist:).tw.
AND randomized controlled trials.sh. OR clinical
trial:.tw. OR random:.tw. Reference lists of reviews were
scanned for additional citations.
Systematic review of the oncology literature on study 
quality
To locate systematic reviews on oncology topics, the strat-
egy suggested by Moher et al for finding systematic
reviews [3] was combined with the terms "neoplasms.sh.
OR cancer.tw. OR carcinoma.tw" to search the Medline,
CINAHL, and Cancerlit databases. To ascertain if the
authors assessed the quality of the studies included in the
systematic reviews, the search was narrowed to include the
terms [(quality adj rat:).tw OR (quality adj assess:).tw. OR
(quality adj scale:).tw. OR (quality adj checklist:).tw. OR
(study adj quality).tw.]. Textwords were used to search the
Cochrane Library for systematic reviews on oncology top-
ics. Systematic reviews that included analyses exploring
the relationship between study quality (using any assess-
ment instrument, not just validated tools that met our cri-
teria as described above) and effect size were examined.BMC Medical Research Methodology 2005, 5:8 http://www.biomedcentral.com/1471-2288/5/8
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Because survival following cancer treatment is commonly
used as the primary outcome variable in our practice
guidelines, this variable was selected as the primary out-
come measure of interest.
Impact of study quality on PEBC practice guidelines
The validated scales were applied by two methodologists
(MJ and MC) to studies reported in any our practice guide-
lines that included a pooled analysis based on at least ten
randomized trials related to the main guideline question.
Intraclass correlation coefficients with 95% confidence
intervals (CI) were calculated using a random sample of
the RCTs to assess inter-rater reliability, one coefficient
calculated for each of the scales used. Because of budget-
ary limitations for staff time, the analysis was conducted
on 18 randomly selected studies rather on the whole
group of articles. This is a methodological limitation as
fewer studies result in larger confidence intervals and less
precise estimates. This may account for the difference in
reliability ratings we found for the Sindu scale compared
to published norms (see Table 1).
To assess the impact of study quality on effect sizes, sensi-
tivity analyses were conducted for the meta-analysis from
each guideline report. For each scale, studies were divided
into two groups (low quality and high quality) based on
total quality score. Where the scale developer suggested a
cut-off point for low versus high quality, this was used.
Where no cut point was specified, the observed median
study quality score was used as the dividing point between
low and high quality. Meta-analyses were repeated with
the high quality studies. Because there would never be a
situation in which guideline developers would consider
low quality studies only, a meta-analysis using this sam-
ple of the studies was not conducted.
Results
Valid and reliable quality assessment tools for our context
Four scales meeting our criteria were found; two instru-
ments, Jadad et al [22] and Cho & Bero [23], were origi-
nally uncovered in the Moher review [21] and two
instruments, Sindhu et al [24] and Downs & Black [25],
were uncovered in our update of this review. While none
of these scales were developed in the oncology setting,
they all purport to be generic assessment tools that meas-
ure the quality of specific study designs regardless of clin-
ical condition reflected in the design. The procedures
undertaken to create the instruments followed appropri-
Table 1: Quality assessment tools with published validity and reliability data – information reported by the scale developers
Instrument Description Item Generation Validity Inter-Rater Reliability Application in Study
Jadad et al (22) number of items: 3 or 6
scoring for 3 item: 0, 1, or 2 
for two items 0 or 1 for 1 
item range 0 to 5
scoring for 6 item: 0, 1, or 2 
for two items 0 or 1 for 4 
items range 0 to 8
cut offs not specified for 
either version
consensus among 6 judges 
(pain management &/or 
instrument development)
pretested with 3 raters on 
13 clinical trial reports
3 groups of pain studies 
were identified a priori:
• studies rated as excellent 
by experts (n = 7); overall 
score = 3.4
• studies rated as poor by 
experts (n = 6); overall 
score = 0.7
• a random selection of 
RCTs from a MEDLINE 
search (n = 23); overall 
score = 2.7
ICC = 0.66 (95% CI: 0.53, 
0.79)
14 raters
3-item and 6-item versions 
in their entirety
Sindhu et al (24) number of items: 53
scoring: items weighted from 
1 to 10 range 0 – 100
cut offs not specified
8-member Delphi panel 
(clinicians and 
methodologists)
Compared with the 
Chalmers scale for five 
studies of non-
pharmacologic nursing 
interventions for pain 
management; r = 0.94 
(Pearson) 11 studies 
considered for a published 
meta-analysis on 
hypertension were 
evaluated:
• 9 included studies scored 
73–93%;
• 2 rejected studies scored 
below 70%
ICC = 0.93
2 raters
12 of 53 items eliminated 
because of difficulty applying 
to cancer studies
41 items related to 12 
domains range 0 – 79.5
Downs & Black (25) number of items: 27
scoring 0 or 1 for 25 items
1 or 2 for 1 item
0 to 5 for 1 item
cut offs not specified
based on epidemiological 
principles, reviews of study 
designs and existing 
checklists
pilot tested by 2 
epidemiologists rating 20 
studies
Compared with the 
Standards of Reporting 
Trials Group checklist scale 
for 10 RCTs on surgery for 
stress incontinence; r = 0.90 
(Spearman)
Spearman r = 0.75
2 raters
used 13 internal validity 
items only
items not related to our 
definition of quality 
eliminated (10 reporting 
items, 3 external validity 
items, 1 power item) range 1 
to 13
RCT, randomized controlled trial; ICC, intraclass correlation coefficient; CI, confidence intervalBMC Medical Research Methodology 2005, 5:8 http://www.biomedcentral.com/1471-2288/5/8
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Table 2: Quality assessment tools – comparison of key quality constructs
Jadad Sindhu Downs & Black
Randomization Max.= 2 points out of total score of 5
1. Was the study described as 
randomized? (1 point for yes) Give an 
additional point if the method to 
generate the sequence of randomization 
was described and it was appropriate. 
Deduct a point if it was inappropriate.
Max. = 10 points out of total score of 100
2. Have the patients been randomly allocated to 
treatment groups? (1 point for yes)
If yes: i) Is the method of randomization 
explicitly detailed? (1.5 points)
ii) Is it valid? i.e. Are there any threats to 
internal validity re: designation of subjects to 
groups? (2.5 points)
iii) Is patient consent sought prior to 
randomization? (2.5 points)
iv) Is it secure and 'blind' to the assessors? (2.5 
points)
Max. = 2 points out of total score of 13
23. Were the study subjects randomised to 
intervention groups? Studies which state that 
subjects were randomised should be answered 
yes except where method of randomisation 
would not ensure random allocation. For 
example alternate allocation would score no... 
(1 point for yes)
24. Was the randomised intervention 
assignment concealed from both patients and 
health care staff until recruitment was complete 
and irrevocable? (1 point)
Blinding Max. = 2 points out of total score of 5
2. Was the study described as double 
blind? (1 point)
Give an additional point if the method of 
double blinding was described and it was 
appropriate. Deduct a point if it was 
inappropriate.
Max. = 5 points out of total score of 100
9. Is the assessment blind?
a) If yes, who is blinded:
i) patients? (2 points)
ii) therapist/carer? (2 points)
iii)assessor/data collector? (1 point) b) If no, i) 
are reasons given as to why assessment is not 
blind? (2 points)
ii) Is there discussion of bias resulting from non-
blind assessment? (3 points)
Max. = 2 points out of total score of 13
14. Was an attempt made to blind study 
subjects to the intervention they have received? 
(1 point)
15. Was an attempt made to blind those 
measuring the main outcomes of the 
intervention? (1 point)
Withdrawals and dropouts 
Intention to treat analyasis
Max.= 1 point out of total score of 5
3. Was there a description of 
withdrawals and dropouts? 1 point)
Max. = 12 points out of total score of 100
6. Has an 'intention-to-treat analysis been 
performed? i.e. everyone randomized is retained 
in the study; everyone randomized is included in 
the final analysis; and no selective dropouts. (8 
points)
b) if not, is it clear what was done, its 
justification and impact on bias? (8 points)
11. Loss to follow-up
a) (<) 20% loss to follow up (2 points)
b) <10% loss to follow-up (2 points)
Max. = 2 points out of total score of 13
25. Was there adequate adjustment for 
confounding in the analyses from which the 
main findings were drawn? The questions should 
be answered no for trials if: the main 
conclusions of the study were based on analyses 
of treatment rather than intention to treat;.... (1 
point)
26. Were losses of patients to follow-up taken 
into account? If the number of patients lost to 
follow-up are not reported, the question should 
be answered unable to determine. If the 
proportion lost to follow-up was too small to 
affect the main findings, the question should be 
answered yes? (1 point)
Appropriate statistical 
analysis
no items Max. = 6 points out of total score of 100
7. Statistical analysis
a) Is the analysis appropriate/specific to the 
hypothesis and to the data? (1 point)
b) Is the analysis adequately described? (1 point)
c) Do the statistical assumptions hold? (1 point)
d) Are adequate summary statistics provided at:
i) baseline? (0.5 point)
ii) outcome? (05. point)
e) Is the overall significance level reported 
protected against inflation due to multiple 
testing? (1 point)
f) If confounders exist, are they adjusted for via 
multivariate techniques even if differences 
between groups are not significant? (1 point)
Max. = 4 points out of total score of 13
16. If an of the results of the study were based 
in 'data dredging', was this made clear? (1 point)
17. Do the analyses adjust for different lengths 
of follow-up of patients? (1 point)
18. Were the statistical tests used to assess the 
main outcomes appropriate? (1 point)
25. Was there adequate adjustment for 
confounding in the analyses from which the 
main findings were drawn? (1 point)
Compliance with 
treatment
no items Max. = 4 points out of total score of 100
14. Has patient compliance been assessed? (4 
points)
Max. = 1 point out of total score of 13
19. Was compliance with the interventions 
reliable? (1 point)
Outcome Measures no items Max. = 14 points out of total score of 100
3. Measurement of outcomes
a) Is the form of measurement stated? (3 points)
b) Has an attempt been made to validate the 
measures? (3 points)
c) Has an attempt been made to test the 
reliability of the measures? (2 points)
d) Is the outcome objective as compared to 
subjective? (2 points)
12. Outcomes
a) How many outcomes are used (1/2 point for 
each, to a max. of 2)
b) Are they relevant? (1 point)
c) Are they independent? (1 point)
Max. = 1 point out of total score of 13
20. Were the main outcome measures used 
accurate (valid and reliable)? (1 point)BMC Medical Research Methodology 2005, 5:8 http://www.biomedcentral.com/1471-2288/5/8
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ate methodological processes for questionnaire design. In
addition, while a number of additional scales and check-
lists emerged from our search, validity and reliability data
were not reported. Because our practice guidelines are
based primarily on evidence from randomized trials, we
decided to reserve to employ the scales that focused spe-
cifically on RCTs. As such, the Cho & Bero scale, which is
applicable to a range of study designs, was not employed
here but will be considered at a later date when we have a
portfolio of diverse study designs. The characteristics of
the instruments included in our study are summarized in
Table 1 and 2 and detailed descriptions and comparisons
can be found in West et al. [4].
The relationship between study quality and effect size in 
the oncology literature
The literature review located 32 published systematic
reviews on oncology-related topics that included some
measure of study quality. Five of the reviews examined
changes in pooled estimates of effect size of mortality
rates when meta-analysis was restricted to high-quality
randomized trials [26-30]. As shown in Table 3, four of
the five reviews found somewhat larger effects (i.e., larger
differences between experimental and control groups)
with high-quality trials compared to all trials [26-29].
With one exception, the statistical relevance of the differ-
ences between the groups (i.e., significant differences or
no significant differences) remained the same regardless
of the number of trials included. Specifically, two of the
reviews did not detect a statistically significant difference
in survival between groups when all studies were included
or when the meta-analysis was restricted to high-quality
studies [26,29]. For one data set, the meta-analysis was
repeated with study quality ratings used as weights [29];
there was still no significant difference between experi-
mental and control groups. Two analyses detected signifi-
Table 3: Systematic reviews of randomized oncology trials with sensitivity analysis exploring the relationship between study quality 
scores and effect sizes for mortality
Systematic 
Review
Interventions Outcome Quality Scale Definition of 
High Quality
Effect Size (95% confidence interval)
All Studies
(# studies)
High Quality
(# studies)
McAlister et al, 
1998 (26)
allogenic blood 
transfusion versus 
autologous or 
leucocyte-depleted 
allogenic blood during 
cancer surgery
relative risk 
of death*
Jadad (22) score ≥ 3 out of 5 RR, 0.94 (0.76 to 1.16) 
(n = 5)
RR, 0.84 (0.47 to 1.52) 
(n = 2)
Caubet et al, 
1997 (27)
nonsteroidal anti-
androgens (plus 
LHRH or 
orchiectomy) versus 
LHRH or 
orchiectomy alone for 
advanced prostate 
cancer
relative risk 
of death*
Chalmers (31) score ≥ 50 % of 
total possible 
score
RR, 0.81 (0.70 to 0.94) 
(n = 13)
RR, 0.78 (0.66 to 0.92) 
(n = 4)
Dube et al, 
1997 (28)
adjuvant 
chemotherapy versus 
control for colorectal 
cancer
odds ratio 
for death*
Chalmers (31) score >50 % of 
total possible 
score
OR, 0.82 (0.77 to 0.89) 
(n = 29)
OR, 0.77 (0.71 to 
0.85) (n = 14)
Detsky et al, 
1992 (29)
total parenteral 
nutrition versus 
control in cancer 
patients undergoing 
chemotherapy
odds ratio 
for survival**
Chalmers (31) score >42 % of 
total possible 
score; quality 
score also used as 
a weighting factor 
in meta analysis
OR, 0.74 (0.42 to 1.3) 
(n = 8)
OR, 0.69 (0.38 to 1.3) 
(n = 2) weighted OR, 
0.61 (0.23 to 1.6)
Klein et al, 
1986 (30)
total parenteral 
nutrition versus 
control in cancer 
patients undergoing 
surgery
odds ratio 
for operative 
death*
Developed 
specifically for 
the systematic 
review
quality score used 
as a weighting 
factor in meta 
analysis
OR, 0.44 (0.21 to 0.90, 
p = 0.02) (n = 10)
weighted OR not 
reported but p = 0.07 
after weighting for 
study quality
LHRH, luteinizing hormone-releasing hormone; RR, relative risk; OR, odds ratio
*RR or OR <1.0 indicates fewer deaths in the experimental group than in the control group
** OR <1.0 indicates more deaths in the experimental group than in the control groupBMC Medical Research Methodology 2005, 5:8 http://www.biomedcentral.com/1471-2288/5/8
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cant differences between experimental and control
treatments with analysis of all trials and when the analysis
was restricted to high-quality trials [27,28]. In the fifth
review, a significant difference between experimental and
control interventions was detected when all trials were
synthesized that became only marginally significant (p <
.07) when the meta-analysis was adjusted for study qual-
ity [30].
Impact of study quality on PEBC practice guidelines
Three of the PEBC practice guidelines included at least 10
RCTs in their systematic reviews of the evidence and were
eligible for inclusion in this evaluation [31-33]: concomi-
tant chemotherapy and radiotherapy in squamous cell
head and neck cancer (18 trials) [31]; adjuvant therapy for
stage II colon cancer following complete resection (11 tri-
als) [32]; and neoadjuvant chemotherapy in locally
advanced squamous cell carcinoma of the head and neck
(23 trials) [33]. For the latter guideline [33], data could
not be reliably reconstructed and is not discussed further.
At the conclusion of our study, we identified a fourth prac-
tice guideline which originally did not meet our 10 RCT
inclusion criteria, but later did so after it was updated. The
guideline focused on the role of erythropoietin (EPO) in
the management of cancer patients with non-hematologic
malignancies [34]. Unlike the chemotherapy trials
included in the practice guidelines described above,
which were not placebo-controlled and where the primary
outcome was death, one-third of the EPO trials were dou-
ble blind and all used the need for blood transfusion as
the primary outcome. Although by the time this practice
guideline emerged as eligible we had identified a preferred
scale (see below), we chose to include it here and apply
only the preferred scale as a demonstration of its use on a
report that had differing characteristics than the chemo-
therapy topics covered.
Inter-rater reliability
Intraclass correlation coefficients used to established
inter-rater reliability were 0.71 for the 3-item Jadad scale
(95% CI, 0.38 to 0.88), 0.80 for the 6-item Jadad scale
(95% CI, 0.54 to 0.92), 0.62 for the Sindhu scale (95% CI,
0.24 to 0.84), and 0.63 for the Downs & Black Scale (95%
CI, 0.25 to 0.84). Disagreements were resolved by consen-
sus. Where consensus could not be reached, a third rater
(MB) assessed the items and provided the tiebreaker
score.
Application of quality scales to primary studies informing practice 
guidelines
While the total quality scores emerging from each of the
different scales did all significantly correlate with one
another (range r = .35 to r = .73), there was considerable
Table 4: Meta-analysis of all trials and high-quality trials from evidence-based practice guidelines
Practice Guideline
Colon Cancer Adjuvant 
chemotherapy 
Outcome: Mortality 
(32)
Head & Neck 
Concomitant therapy 
Outcome: Mortality 
(31)
Systemic Therapy 
erythropoietin 
Outcome: need for 
blood transfusion (34)
All Studies # studies
(# comparisons)
11 (11) 18 (20) 15 (15)
OR (CI) 0.82 (0.62 – 1.09) 0.62 (0.54 – 0.72) 0.57 (0.47–0.70)
High Quality 
Studies By 
Assessment Scale 
Criteria
Jadad (3-item) range = 
0–5 criteria >2
# studies
(# comparisons)
0 2 (2) not applied
OR (CI) - 0.54 (0.34 – 0.86)
Jadad (6-item) range = 
0–8 criteria >3
# studies
(# comparisons)
8 (8) 13 (14) 9 (9)
OR (CI) 0.88 (0.69–1.13) 0.53 (0.44 – 0.64) 0.57 (0.44–0.72)
Sindhu (41-item) 
range = 0–79.5 
criteria > 44.8
# studies
(# comparisons)
9 (9) 11 (12) not applied
OR (CI) 0.86 (0.68–1.09) 0.62 (0.49 – 0.79)
Downs & Black (13-
item) range = 0–13 
criteria > 7
# studies
(# comparisons)
6 (6) 12 (14) not applied
OR (CI) 0.86 (0.59–1.25) 0.56 (0.46 – 0.68)
OR, odds ratio; CI, 95% confidence intervalBMC Medical Research Methodology 2005, 5:8 http://www.biomedcentral.com/1471-2288/5/8
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variation in the classification of studies as high quality or
low quality as a function of the scale that was applied
(Table 4). For example, of the 11 comparisons from 11
trials comprising the stage II colon cancer review, the
application of the Jadad 3-item, the Jadad 6-item, the
Sindhu, and Downs & Black scales yielded 0, 8, 9, and 6
of these as high quality, respectively. The 6 studies catego-
rized as high quality using the Downs & Black tool were
also categorized as high quality when the Jadad 6-item
and Sindhu scales were applied. Similarly, the 8 studies
categorized as high by the Jadad 6-item were also catego-
rized as high quality by the Sindhu scale.
The 20 comparisons from the 18 trials included in the
head and neck concomitant therapy systematic review
yielded 2, 14, 12 and 14 high quality studies, respectively,
when the Jadad 3-item, the Jadad 6-item, the Sindhu and
the Downs & Black scales was used. Although both Jadad
6-item and Downs & Black scales both assessed 14 com-
parisons to be from high quality studies, only 11 of these
14 studies were the same. For the 12 comparisons from
studies categorized as high quality with the Sindhu scale,
10 of these were also rated high quality by both the Jadad
6-item and the Downs & Black scales, the other 2 were
rated as high quality by the Jadad 6-item scale only. There
was 1 comparison from a study rated as high quality by
the Jadad 6-item scale only and two from studies rated as
high quality by the Downs & Black scale only.
Impact on pooled estimates of outcome measures
Mortality data (i.e., numbers of deaths and number of
patients randomized for each allocation group, abstracted
from published trial reports) used for the meta-analysis
included in the guideline reports were available for two
guidelines and need for blood transfusion data were avail-
able for the third [31,32,34]. For each guideline, the
pooled odds ratio based on only the high-quality trials
was compared with the odds ratio from meta-analysis of
all trials that had been included originally in the review
(Table 4). For the first guideline [31], there was a signifi-
cant survival benefit for concomitant chemotherapy and
radiotherapy compared with radiotherapy alone for squa-
mous cell head and neck cancer in the meta-analyses that
included all studies and the meta-analyses restricted to
high quality studies, regardless of quality appraisal tool
used. Although the effect size was larger for meta-analysis
of high-quality RCTs than for all RCTs (irrespective of
quality scale used), the confidence intervals between the
two calculations overlapped and the overall conclusions
and the recommendations informed by the meta-analysis
would have been the same. For the second guideline [32],
no survival benefit was detected for adjuvant chemother-
apy compared to standard therapy for stage II colon can-
cer in the meta-analysis of all the studies or the high
quality studies, again, regardless of quality appraisal tool
used. Although the meta-analysis of the high study quality
studies was associated with smaller effect sizes than the
calculation including all of the studies, the confidence
intervals overlapped and the conclusions and the recom-
mendations would have remained the same.
Only the 6-item Jadad scale was applied to the studies of
the EPO guideline and the data were pooled to calculate
an overall risk ratio for blood transfusion [34]. The risk
ratio for all 15 trials was 0.57 (95% CI, 0.47 to 0.70); for
nine trials that scored more than three out of eight on the
6-item Jadad scale, the risk ratio was also 0.57 (95% CI,
0.44 to 0.72) (see Table 4).
Conclusions
Several conclusions can be drawn from this study and
review of the literature. First, there are established meth-
ods for assessing the quality of randomized controlled tri-
als in which data on adequate reliability and validity were
available. West et al uncovered 32 scales, check lists and
component systems concerned with evaluating RCTs [4];
more than the four strategies we applied here. Although
most (87%) of the instruments found by West included
quality domains for which there is an empirical basis,
most failed to report the use rigorous methods in their
development and most failed to report data regarding reli-
ability and validity, criteria we set for our study. Interest-
ingly, West et al did not include the Jadad 6-item in their
analysis [4], although the Jadad 3-item, Downs & Black,
and Sindhu tools were reported.
Although all of the scales we used have established relia-
bility and validity estimates, we found that the number of
trials categorized as high quality or low quality depended
specifically on the scale that was applied. For the head and
neck cancer systematic review, the number comparisons
from high quality studies ranged from 2 (when the Jadad
3-item scale was applied) to 14 (when the Jadad 6-item or
Downs & Black scales were applied). The range for the
colon cancer review was 0 to 9. There was also considera-
ble variability regarding the specific quality category in
which each trial was placed. These finding are consistent
with those of Juni et al [14] and suggest caution should be
applied if the intent of quality rating scales is to restrict the
number of studies considered in the systematic review;
clearly the choice of scale will have a significant impact
regarding what studies are eligible. The problem of identi-
fying to which quality category, high or low, studies
should be placed is exacerbated by the lack of clear cut-off
criteria identified by the instrument developers. This
poses a significant methodological limitation to the utility
of these instruments. In our study, we chose the median
score as the cut-off criteria in situations where none was
reported. However, it would be useful for researchers of
these tools to continue the development work to createBMC Medical Research Methodology 2005, 5:8 http://www.biomedcentral.com/1471-2288/5/8
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the evidence-base from which valid criteria can be
established.
The lack of consistency of study classification from one
scale to the next and the lack of clear cut-off criteria for
users to employ when measuring quality of studies,
presents a challenge to guideline developers when they
need to make choice about which instrument they ought
to adopt if the choose to adopt an instrument at all. Rather
than clear evidence driving our decisions, we considered
other features of the instrument in our decision making.
Of the rating scales we examined, our preferred choice
would be the Jadad 6-item instrument. In contrast to the
others considered in this report, this instrument is rela-
tively easy to implement and interpret and good inter-
rater reliability was established. Further, although the 3-
item version of the Jadad scale is most commonly used,
we found the original 6-item version to be more relevant
in our clinical context as it provides greater variation in
scores. In the cancer discipline, few trials are placebo-con-
trolled and treatment allocation tends to be poorly
reported. In contrast to the pain trials which were profiled
in the development phase of the Jadad instrument, the
majority of the items in the 3-item version (randomiza-
tion and blinding items) yield no variation in scores in
our context and are, therefore, not useful to discriminate
among cancer trials. The 6-item version of the scale more
aptly differentiates quality across studies and includes
more quality domains for which an empirical basis has
been established [4].
Another conclusion that can be drawn from this study is
that effect size can be related to study quality but that the
nature of the relationship in one clinical area may not
generalize to another clinical area. Some of the original
work examining the role of study quality reinforces the
need to be mindful of the variation among studies
included in systematic review [5-7]. However, when we
examined five published reviews that had conducted sen-
sitivity analyses on pooled mortality data from RCTs, four
of these found that larger effect sizes were associated with
high-quality studies, not lower quality trials as has been
convention, and the absence or presence of statistical dif-
ferences between the two allocation groups remained con-
stant. One of challenges in examining this work is that the
number of high quality studies is limited; there is a reduc-
tion in power that subjects the point estimates to bias.
Nonetheless, the potential bias of study design and
quality requires thoughtful consideration within a given
clinical field.
We conducted sensitivity analysis on the systematic
reviews comprising the guidelines developed by the
PEBC. Only four systematic reviews among 36 eligible
practice guidelines included more than 10 trials with data
appropriate for pooling; three from which we could
extract data. Although there was some variation in the
odds ratios observed, the confidence intervals of the
pooled effects from each of the analyses of high quality
trials overlapped with the confidence intervals of the
pooled odds with all of the trials. In no case would the
conclusions based on these results be affected by restrict-
ing the meta-analysis to only high quality studies; the rec-
ommendations remained the same. Had sensitivity
analysis based on study quality been conducted prospec-
tively, it is highly unlikely that different conclusions
would have been drawn from the systematic review or that
different clinical practice guidelines would have been
formulated.
Together, these findings lead to our final conclusion that
measuring study quality did not translate into altered con-
clusions from a systematic review in the oncology domain
for the outcomes we used here. Thus, at this time we have
decided that measuring study quality using a numerical
assessment scale for the purposes of sensitivity analysis
will not be a routine part of our guideline development
program. We will, however, encourage guideline develop-
ers to describe the variation among studies and to point
out methodologic flaws. In addition, it will be important
for us to repeat this study looking at other outcome meas-
ures, such as quality of life and adverse effects, as they
become more routinely reported in primary cancer
research and incorporated into our practice guidelines.
Outcomes other than those studied here may be more
sensitive to the issues of study quality.
This study highlights a strategy that may be useful for
guideline programs to utilize in making decisions regard-
ing the methods employed in their guideline develop-
ment process. It is important that scientific inquiry be
maintained in studying the value and role of study quality
assessment rather than accepting its role as convention. By
exploring it within a specific clinical context one can iden-
tify it's most appropriate application.
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